Anika Therapeutics (ANIK) Receivables: 2010-2025
Historic Receivables for Anika Therapeutics (ANIK) over the last 14 years, with Sep 2025 value amounting to $23.1 million.
- Anika Therapeutics' Receivables fell 25.45% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year decrease of 25.38%. This contributed to the annual value of $24.3 million for FY2024, which is 10.00% down from last year.
- As of Q3 2025, Anika Therapeutics' Receivables stood at $23.1 million, which was down 6.86% from $24.8 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Receivables registered a high of $38.4 million during Q2 2023, and its lowest value of $22.7 million during Q1 2025.
- For the 3-year period, Anika Therapeutics' Receivables averaged around $29.9 million, with its median value being $30.9 million (2024).
- In the last 5 years, Anika Therapeutics' Receivables spiked by 40.61% in 2021 and then plummeted by 32.70% in 2025.
- Over the past 5 years, Anika Therapeutics' Receivables (Quarterly) stood at $31.3 million in 2021, then climbed by 15.82% to $36.2 million in 2022, then decreased by 25.41% to $27.0 million in 2023, then fell by 10.00% to $24.3 million in 2024, then decreased by 25.45% to $23.1 million in 2025.
- Its Receivables stands at $23.1 million for Q3 2025, versus $24.8 million for Q2 2025 and $22.7 million for Q1 2025.